SCHEMBL4856385

SCHEMBL4856385

CCOP(=O)(OCC)C(CC(=O)c1ccc2ccccc2c1)NC(=O)OCC(Cl)(Cl)Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ THRB P10828 2/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ HPGD P15428 2/20 0.41
▸ GAA P10253 1/20 0.41
▸ MAPT P10636 1/20 0.40
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ EPHX2 P34913 1/20 0.37
▸ PIN1 Q13526 2/20 0.37
▸ ADRB2 P07550 1/20 0.36
▸ ADRB1 P08588 1/20 0.36
▸ ADRB3 P13945 1/20 0.36
▸ P2RY12 Q9H244 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ HDAC3 O15379 1/20 0.36
▸ HDAC1 Q13547 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4856386 1.00 MEN1 (0.44) MEN1KMT2ASMN1; SMN2THRBL3MBTL1
SCHEMBL5712075 0.88 SMN1; SMN2 (0.53) MEN1KMT2ASMN1; SMN2THRBL3MBTL1
SCHEMBL4848464 0.88 SMN1; SMN2 (0.53) MEN1KMT2ASMN1; SMN2THRBL3MBTL1
SCHEMBL4853702 0.86 MAPT (0.41) SMN1; SMN2HPGDMAPT
SCHEMBL4853697 0.86 MAPT (0.41) SMN1; SMN2HPGDMAPT
SCHEMBL4852578 0.85 MAPT (0.42) MEN1KMT2ASMN1; SMN2ALDH1A1GAA
SCHEMBL4852576 0.85 MAPT (0.42) MEN1KMT2ASMN1; SMN2ALDH1A1GAA
SCHEMBL4856844 0.85 MAPT (0.54) MEN1KMT2ASMN1; SMN2THRBL3MBTL1
SCHEMBL4856854 0.85 MAPT (0.54) MEN1KMT2ASMN1; SMN2THRBL3MBTL1
SCHEMBL4845951 0.85 MAPT (0.43) SMN1; SMN2THRBL3MBTL1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1724275-B1 PROCESS FOR PRODUCING AMINOPHOSPHONIC ACID DERIVATIVE JAPAN SCIENCE & TECH AGENCY (JP) 2015-04-08 — — EP disclosed
US-7375244-B2 Production method for aminophosphonic acid derivatives JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2008-05-20 — — US disclosed
US-20070142658-A1 Production method for aminophosphonic acid derivatives JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2007-06-21 — — US disclosed
EP-1724275-A1 PROCESS FOR PRODUCING AMINOPHOSPHONIC ACID DERIVATIVE Japan Science and Technology Agency (JP) 2006-11-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142658-A1 Production method for aminophosphonic acid derivatives AASDHPPT, NPEPPS, DAO MEN1 1745/4885KMT2A 3395/4885SMN1; SMN2 2825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback